Cancer patients who suffer a heart attack face a dangerous mix of risks, which makes their clinical treatment particularly challenging. As a result, patients with cancer have been systematically ...
The FDA accepted the BLA for ivonescimab plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer post-TKI ...